The present invention relates to suspension, and it includes the ophthalmically acceptable active component being suspended in the preparations carrier comprising suspending agent and nonionic cellulose derivatives.The ophthalmically acceptable activating agent is with Dv90<;5 μm and Dv50<;1 μm of particle is present.The suspension can be applied to patient to treat ophthalmic inflammatory illness.